Publications

2024

• Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.
• Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.
• Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease.
• Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.
• Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.
• Dementia in Down syndrome
• Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome.
• A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease.
• Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions.
• Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease.
• Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
• Associations between misfolded alpha-synuclein aggregates and Alzheimer’s disease pathology in vivo.
• Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies.
• The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
• The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation
• Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
• Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
• MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
• Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model
• A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease
• Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
• Divergent functional connectivity changes associated with white matter hyperintensities
• Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
• Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
• A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
• A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests
• Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
• Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
• Revised criteria for the diagnosis and staging of Alzheimer’s disease
• Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
• Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
• Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
• In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives
• Structural and functional connectivity associations with anterior cingulate sulcal variability
• Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
• MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults
• Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
• Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology
• Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer’s disease
• Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
• Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling
• A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variables
• Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
• Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease
• Disease staging of Alzheimer’s disease using a CSF-based biomarker model
• Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison
• Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
• Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
• Biomarker-based staging of Alzheimer disease: rationale and clinical applications
• Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia
• Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
• Altered empathy processing in frontotemporal dementia A task-based fMRI study
• Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
• Is GBA1 T369M not a risk factor for Parkinson’s disease in the Swedish population?
• A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
• Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease.
• Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.
• Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.
• Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease.
• Prognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review.
• Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.
• The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology.
• Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
• Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
• Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.
• Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
• Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease.
• Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology.
• The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App^NL-F/NL-F mice.
• Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.

2023

• Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.
• The molecular genetic landscape of human brain size variation.
• Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment.
• The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
• DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
• A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.
• Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
• Clinical effects of Lewy body pathology in cognitively impaired individuals.
• CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.
• Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
• Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
• Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology.
• Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
• Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
• Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer’s disease.
• Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.
• Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders.
• Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.
• Blood biomarkers for Alzheimer’s disease in clinical practice and trials.
• CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease.
• Age-related and amyloid-beta-independent tau deposition and its downstream effects.
• Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App^NL-F/NL-F knock-in mouse model of Alzheimer’s disease.
• Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease.
• Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
• Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
• Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease.
• Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
• Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
• Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
• Novel insights regarding the measurement properties of the SCOPA-AUT.
• [¹⁸F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.
• Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.
• The genetic regulation of protein expression in cerebrospinal fluid.
• Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson’s Disease and Related Disorders.
• Performance of [¹⁸F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.
• Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease.
• CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers.
• Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease.
• Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease.
• Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.
• Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease.
• Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance.
• Clinical performance and robustness evaluation of plasma amyloid-β_42/40prescreening.
• Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease.
• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.
• Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
• Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia.
• Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.

2022

• Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
• Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.
• An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.
• Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
• Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.
• Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.
• Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.
• β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
• Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.
• Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.
• Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.
• Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.
• Subtypes of Alzheimer’s disease: questions, controversy, and meaning.
• Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
• The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
• Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.
• Components of gait in people with and without mild cognitive impairment.
• Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
• Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
• Blood-based biomarkers for Alzheimer’s disease.
• Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.
• Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.
• Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
• Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.
• Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
• Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.
• The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
• Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.
• Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
• Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.
• Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

2021

• Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.
• Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
• Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
• Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
• Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
• The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.
• Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.
• Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
• The global Alzheimer’s Association round robin study on plasma amyloid β methods.
• Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.
• Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
• Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
• Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
• Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.
• Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.
• Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.
• Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.
• Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
• Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
• Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.
• A multicentre validation study of the diagnostic value of plasma neurofilament light.
• Sex differences in off-target binding using tau positron emission tomography.
• Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
• The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
• A multicenter comparison of [¹⁸F]flortaucipir, [18F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.
• Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
• Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.
• Four distinct trajectories of tau deposition identified in Alzheimer’s disease.
• Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.
• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.
• Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.
• The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.
• Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.
• Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.
• Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.
• A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [¹⁸F]flutemetamol amyloid PET images.
• Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.
• Biomarker testing in MCI patients-deciding who to test.
• Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
• Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.
• Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
• Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.
• Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
• Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.
• Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.
• The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
• Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.
• Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

2020

• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
• Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease
• Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia
• Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease
• Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
• Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease.
• Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.
• Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease.
• Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease.
• Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease.
• The impact of demographic, clinical, genetic, and imaging variables on tau PET status.
• Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age.
• Image reconstruction methods affect software-aided assessment of pathologies of [¹⁸F]flutemetamol and [¹⁸F]FDG brain-PET examinations in patients with neurodegenerative diseases.
• Validation of a spatial normalization method using a principal component derived adaptive template for [¹⁸F]florbetaben PET.
• Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.
• The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people.
• Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease.
• Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.
• CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers.
• Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
• The implications of different approaches to define AT(N) in Alzheimer disease.
• Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
• Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
• Relationship between cortical iron and tau aggregation in Alzheimer’s disease.
• Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease.
• Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease.
• The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment.
• Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding.
• Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease.
• [¹⁸F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case.
• Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. 
• Head-to-head comparison of tau positron emission tomography tracers  [¹⁸F]flortaucipir and [¹⁸F]RO948.
• Apathy and anxiety are early markers of Alzheimer’s disease.
• Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease.

2019

• Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume.
• Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
• Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. 
• Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity.
• Predicting Clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
• Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.
• Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. 
• A quick test of cognitive speed can predict development of dementia in Parkinson’s disease. 
• Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.
• Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
• Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. 
• Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease.
• β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. 
• α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients.  
• Determining clinically meaningful decline in preclinical Alzheimer disease.
• Towards a unified protocol for handling of CSF before β-amyloid measurements. 
• Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. 
• Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.
• European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). 
• Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. 
• Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. 
• Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. 
• Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. 
• Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. 
• Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.
• Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease. 
• CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia. 
• Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Cross-validation study of practical algorithms. 
• Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. 
• Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease.
• Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. 
• Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. 
• Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. 
• Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. 

2018

• Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
• Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology.
• CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
• Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.
• Exploring causality of the association between smoking and Parkinson’s disease.
• Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer’s disease.
• Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.  
• Parkinson’s disease: evolution of cognitive impairment and CSF Aβ_1-42 profiles in a prospective longitudinal study.  
• Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders.
• Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study. 
• Regional times to equilibria and their impact on semi-quantification of [₁₈F]AV-1451 uptake.
• The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A Review.  
• Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?
• Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic Review.
• Alzheimer’s Disease Neuroimaging Initiative. Amyloid pathology in the progression to mild cognitive impairment.
• Altered structural network organization in cognitively normal individuals with amyloid pathology. 
• Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
• Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages.
• Amyloid blood biomarker detects Alzheimer’s disease.
• Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease.
• Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms.
• 18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.  
• Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease. 
• Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study. 
• Comparing 18F-AV-1451 with CSF T-tau and P-tau for diagnosis of Alzheimer’s disease. 
• CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
• Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later

2017

• Performance of Different Amyloid Immunoassays in Predicting Outcome of Visual Assessment of Amyloid PET Imaging
• The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals.
• Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease.
• The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease.
• A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. 
• CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.
• Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. 
• Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders. 
• Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. 
• Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.
• Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment 
• Atrophy of the posterior subiculum is associated with memory impairment, tau- and Aβ pathology in non-demented individuals.
• In vivo retention of (18)F-AV-1451 in corticobasal syndrome.
• Distinct 18F-AV- 1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease.
• 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. 
• Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
• Psychometric testing of a Swedish version of the Apathy Evaluation Scale.
• Tau oligomers in cerebrospinal fluid in Alzheimer’s disease.
• Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.
• Tau Pathology Distribution in Alzheimer’s disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks.
• Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.
• Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
• Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregationn in Alzheimer´s disease

2016

• Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology
• Plasma tau in Alzheimer disease
• Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy
• Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?
• 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.
• Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease.
• Brain activity and Alzheimer’s disease: a complex relationship.
• Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio – a cross-validation study against amyloid PET.
• Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.
• A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease.
• Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42 /Aβ1-40 ratio – a cross-validation study against Amyloid PET.
• Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease.
• Plasma β-amyloid in Alzheimer’s disease and vascular disease
• Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.
• Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson’s Disease Dementia.
• Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation.
• Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
• Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease.
• Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study
• Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease.
• Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
• Early myo-inositol changes may precede Aβ pathology and relate to APOE genotype in Alzheimer disease
• Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls.
• Flt3 ligand does not differentiate between Parkinsonian disorders.
• Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
• Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
• Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
• Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study.
• Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
• Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism
• Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease

2015

• CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios improve the diagnostic accuracy for Alzheimer’s disease
• Increased cerebrospinal fluid biomarkers of angiogenesis in Parkinson’s disease.
• Comparison of Amyloid PET and CSF Biomarkers for Identifying Early Alzheimer’s Disease
• Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
• Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study.
• Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-sectional Cohort Study Evaluating the Effect of Arterial Stiffness.
• Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-sectional Cohort Study Evaluating the Effect of Arterial Stiffness
• CSF biomarkers and clinical progression of Parkinson disease

2014

• Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease
• Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid beta-Amyloid 42
• Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
• Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies

2013

• Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment
• Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography
• Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy

2012

• Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases